Patient demographics
| Demographic . | All patients (N = 119) . | Spliceosome (n = 39) . | Wild-type (n = 80) . | P . |
|---|---|---|---|---|
| Age, median (range), y | 72 (40-89) | 75 (56-85) | 70 (40-89) | .047 |
| Male, n (%) | 65 (55) | 33 (85) | 32 (40) | <.01 |
| ECOG, median (range) | 1 (0-3) | 1 (0-3) | 1 (0-3) | .11 |
| Median WBC (range), ×103/μL | 3.1 (0.3-81) | 3.6 (0.3-81) | 2.9 (0.5-43) | .61 |
| Treatment duration, median (range), mo | 5.7 (0.1-43) | 5.5 (0.5-43) | 5.7 (0.1-32) | .90 |
| Treatment regimen, n (%) | ||||
| Azacitidine + venetoclax | 14 | 3 (8) | 11 (14) | .54 |
| 5-d decitabine + venetoclax | 5 | 2 (5) | 3 (4) | .66 |
| 10-d decitabine + venetoclax | 100 | 34 (87) | 66 (83) | .60 |
| FLT3 inhibitor | 14 (12) | 2 (5) | 12 (15) | .14 |
| Disease, n (%) | ||||
| De novo AML | 70 (59) | 24 (62) | 46 (58) | |
| sAML | 20 (17) | 8 (21) | 12 (15) | .44 |
| MDS | 17 | 7 | 10 | — |
| MPN | 3 | 1 | 2 | — |
| tAML | 29 (24) | 7 (18) | 22 (28) | .36 |
| ELN risk group, n (%) | ||||
| Favorable | 28 (24) | 11 (28) | 17 (21) | .49 |
| Intermediate | 19 (16) | 7 (18) | 12 (15) | .79 |
| Adverse | 72 (61) | 21 (54) | 51 (64) | .32 |
| Cytogenetic group, n (%) | ||||
| Diploid | 39 (33) | 14 (36) | 25 (31) | .68 |
| Other intermediate | 30 (25) | 14 (36) | 16 (20) | .07 |
| Adverse/complex | 50 | 11 (28) | 39 (49) | .047 |
| Demographic . | All patients (N = 119) . | Spliceosome (n = 39) . | Wild-type (n = 80) . | P . |
|---|---|---|---|---|
| Age, median (range), y | 72 (40-89) | 75 (56-85) | 70 (40-89) | .047 |
| Male, n (%) | 65 (55) | 33 (85) | 32 (40) | <.01 |
| ECOG, median (range) | 1 (0-3) | 1 (0-3) | 1 (0-3) | .11 |
| Median WBC (range), ×103/μL | 3.1 (0.3-81) | 3.6 (0.3-81) | 2.9 (0.5-43) | .61 |
| Treatment duration, median (range), mo | 5.7 (0.1-43) | 5.5 (0.5-43) | 5.7 (0.1-32) | .90 |
| Treatment regimen, n (%) | ||||
| Azacitidine + venetoclax | 14 | 3 (8) | 11 (14) | .54 |
| 5-d decitabine + venetoclax | 5 | 2 (5) | 3 (4) | .66 |
| 10-d decitabine + venetoclax | 100 | 34 (87) | 66 (83) | .60 |
| FLT3 inhibitor | 14 (12) | 2 (5) | 12 (15) | .14 |
| Disease, n (%) | ||||
| De novo AML | 70 (59) | 24 (62) | 46 (58) | |
| sAML | 20 (17) | 8 (21) | 12 (15) | .44 |
| MDS | 17 | 7 | 10 | — |
| MPN | 3 | 1 | 2 | — |
| tAML | 29 (24) | 7 (18) | 22 (28) | .36 |
| ELN risk group, n (%) | ||||
| Favorable | 28 (24) | 11 (28) | 17 (21) | .49 |
| Intermediate | 19 (16) | 7 (18) | 12 (15) | .79 |
| Adverse | 72 (61) | 21 (54) | 51 (64) | .32 |
| Cytogenetic group, n (%) | ||||
| Diploid | 39 (33) | 14 (36) | 25 (31) | .68 |
| Other intermediate | 30 (25) | 14 (36) | 16 (20) | .07 |
| Adverse/complex | 50 | 11 (28) | 39 (49) | .047 |
ECOG, Eastern Cooperative Oncology Group; MPN, myeloproliferative neoplasm; WBC, white blood cell.